Get the Stockscreener App
27.62
1.35%
-0.23
Viking Therapeutics Inc stock is traded at $27.62, with a volume of 1.34M.
It is down -1.35% in the last 24 hours and up +18.94% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$27.85
Open:
$27.97
24h Volume:
1.34M
Relative Volume:
0.29
Market Cap:
$3.21B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-29.70
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-6.42%
1M Performance:
+18.94%
6M Performance:
-59.88%
1Y Performance:
-65.74%
1-Day Range:
$27.45
$28.73
1-Week Range:
$26.37
$29.73
52-Week Range:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
27.63 | 3.21B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.84 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
530.32 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.24 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
252.05 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.91 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Why Viking Therapeutics (VKTX) Stock is Gaining Today - GuruFocus
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April - Yahoo
Viking Therapeutics (VKTX) Sees Unusual Options Activity | VKTX Stock News - GuruFocus
Why Viking Therapeutics Stock Surged Nearly 20% Higher In April - Barchart.com
Why Viking Therapeutics Stock Was Victorious This Week - MSN
(VKTX) Investment Report - news.stocktradersdaily.com
Viking Therapeutics (VKTX) Sees 20% Stock Surge Despite Financial Losses - GuruFocus
Why Viking Therapeutics (VKTX) Stock is Rising Today - GuruFocus
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Viking Therapeutics (VKTX) Sees Surge in Call Options Trading | VKTX Stock News - GuruFocus
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025 - simplywall.st
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - The Globe and Mail
This Soaring Stock Just Delivered More Good News. Time to Buy? - AOL.com
Where Will Viking Therapeutics Be in 3 Years? - Yahoo Finance
1 Beaten-Down Stock to Buy and Hold for 10 Years - Yahoo Finance
BlackRock, Inc. Reduces Stake in Viking Therapeutics Inc - GuruFocus
Viking Therapeutics (VKTX) Sees Boost After Pfizer's Acquisition Plans - GuruFocus
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain - Nasdaq
Viking stock rises as Pfizer ups deal prospects (VKTX:NASDAQ) - Seeking Alpha
Why Viking Therapeutics Stock Popped Again Today - MSN
VKTX Stock Surges Amid Analyst Optimism on VK2735 - GuruFocus
Cantor Fitzgerald starts Viking Therapeutics stock with Overweight By Investing.com - Investing.com India
Cantor Fitzgerald starts Viking Therapeutics stock with Overweight - Investing.com
Cantor Fitzgerald initiated coverage on Viking Therapeutics with a new price target - Quantisnow
Why Viking Therapeutics (VKTX) Stock is On the Move - GuruFocus
Viking Therapeutics (VKTX) Sees Stock Rise Despite Increased Los - GuruFocus
Viking Therapeutics (VKTX) Gains Overweight Rating from Cantor F - GuruFocus
Why Viking Therapeutics Stock Popped Today - MSN
Viking Therapeutics (VKTX) Price Target Reduced Amid Competitive Obesity Market | VKTX Stock News - GuruFocus
Viking Therapeutics price target lowered to $75 from $95 at Truist - TipRanks
Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh - GuruFocus
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips - MSN
Viking Therapeutics targets 2025 Phase 3 trials for VK2735 obesity program with promising results - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Viking Therapeutics EPS Miss Overlooked as Long-Term Pipeline Gains Focus - Investing.com
Viking Therapeutics Stock May Struggle After As-Expected Report - MarketBeat
Viking Therapeutics, Inc. SEC 10-Q Report - TradingView
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss for Q1 2025 - simplywall.st
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viking Therapeutics Inc Stock (VKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rouan Sarah Kathryn | Director |
Mar 31 '25 |
Buy |
24.15 |
1,240 |
29,943 |
1,240 |
| Lian Brian | President & CEO |
Jan 06 '25 |
Sale |
42.75 |
194,490 |
8,313,601 |
2,366,570 |
| Mancini Marianna | Chief Operating Officer |
Jan 06 '25 |
Sale |
42.75 |
54,215 |
2,317,599 |
374,134 |
| ZANTE GREG | Chief Financial Officer |
Jan 06 '25 |
Sale |
42.75 |
50,309 |
2,150,595 |
165,259 |
2.11%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):